Monday, October 07, 2024 11:18:30 AM
abnormal volume today, vol over 200k with large blocks traded 1.27-1.275
Bullish
-------------------------------------------------------------------
All posts are strictly my opinion and are not buy or sell recommendations.
Recent BRNS News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 10:03:12 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/30/2026 11:43:29 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 11:32:43 AM
- Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments • GlobeNewswire Inc. • 04/30/2026 11:30:00 AM
- Form DEFM14A - Definitive proxy statement relating to merger or acquisition • Edgar (US Regulatory) • 04/30/2026 10:00:29 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/22/2026 08:30:26 PM
- Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 04/13/2026 07:33:33 PM
- Barinthus Bio Reports 2025 Results and Moves Forward with Planned Clywedog Merger • IH Market News • 03/13/2026 03:29:13 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/13/2026 12:13:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2026 12:03:44 PM
- Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments • GlobeNewswire Inc. • 03/13/2026 12:00:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 02/23/2026 11:29:54 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2026 11:02:42 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/06/2026 09:09:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/10/2025 01:05:05 PM
- Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease • GlobeNewswire Inc. • 12/10/2025 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2025 12:40:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2025 12:34:18 PM
- Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments • GlobeNewswire Inc. • 11/07/2025 12:30:00 PM
- ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics • PR Newswire (US) • 10/24/2025 03:00:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 09/30/2025 08:01:27 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 09/30/2025 12:20:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/30/2025 12:16:58 PM
- Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases • GlobeNewswire Inc. • 09/30/2025 12:00:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 08/08/2025 08:20:09 PM
